Clinical characteristics, patient selection and clinical outcomes of tafamidis treatment in transthyretin amyloidosis cardiomyopathy

Back

ESC Professional Premium Access

Clinical characteristics, patient selection and clinical outcomes of tafamidis treatment in transthyretin amyloidosis cardiomyopathy

Session: Chronic heart failure - Amyloidosis

Topic: Pharmacotherapy

Speaker: Doctor S. Takashio (Kumamoto, JP)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Seiji Takashio

Kumamoto University, Kumamoto (Japan)

0 follower

6 more presentations in this session

Diagnostic accuracy of amyloid scintigraphy for the histopathological diagnosis of cardiac transthyretin amyloidosis - a retrospective Austrian multicenter study

Speaker: Doctor N. Verheyen (Graz, AT)

Access

Abstract

Slides

The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis

Speaker: Assistant Professor A. Briasoulis (Athens, GR)

Access

Abstract

Slides

Hypertension is associated with more advanced heart failure in african americans with suspected cardiac amyloidosis

Speaker: Doctor S. Manjunath (Saint Louis, US)

Access

Abstract

Slides

Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy

Speaker: Professor R. Witteles (Stanford, US)

Access

Abstract

Slides

Histological validation of cardiac 99mTc-DPD uptake in patients with cardiac transthyretin amyloidosis

Speaker: Doctor M. Ungericht (Innsbruck, AT) Associate Professor G. Polzl (Innsbruck, AT)

Access

Abstract

Slides

Access the full session

Chronic heart failure - Amyloidosis

Speakers: Doctor S. Takashio, Doctor N. Verheyen, Assistant Professor A. Briasoulis, Doctor S. Manjunath, Professor R. Witteles...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources